Orthogonal analytical insights from RNA drug substances to lipid nanoparticle drug products

Callum G. Davidson, Eleni Kapsali, Yvonne Perrie, Zahra Rattray*

*Corresponding author for this work

Research output: Contribution to conferencePoster

16 Downloads (Pure)

Abstract

• Polyadenylic acid (Poly(A)) has emerged as a popular choice for use as a model RNA drug substance for LNP formulation prototyping.

• In the absence of existing RNA and LNP drug substance/drug product reference materials, Poly(A)-LNPs are widely used as a control formulation to assess the impact of manufacturing process parameters on formulation critical quality attributes (CQAs).

• Since the stability of RNA drug substance (DS) cargo is a major determinant of drug product (DP) performance, both pre-formulation and post-formulation attributes of the RNA must be assessed thus highlighting the need for systematic comparison of DS quality and its effect on DP formulation.

• This study aims to enhance knowledge of model Poly(A) critical quality attribute impact on LNP formulation attributes, ultimately seeking to produce better standardised controls for LNP bench to bedside translation.
Original languageEnglish
Number of pages1
Publication statusPublished - 8 Sept 2025
Event16th PharmSci International Conference - Principality Stadium, Cardiff, United Kingdom
Duration: 9 Sept 202511 Sept 2025
https://apsgb.co.uk/pharmsci-2025/

Conference

Conference16th PharmSci International Conference
Abbreviated titlePharmSci 2025
Country/TerritoryUnited Kingdom
CityCardiff
Period9/09/2511/09/25
Internet address

Funding

We acknowledge funding from EPRSC (EP/V028960/01) Multiscale Metrology Suite for next-generation health nanotechnologies. We acknowledge and thank EPRSC for funding my PhD scholarship

Keywords

  • Poly(A)
  • lipid nanoparticle
  • analytics
  • translation

Fingerprint

Dive into the research topics of 'Orthogonal analytical insights from RNA drug substances to lipid nanoparticle drug products'. Together they form a unique fingerprint.

Cite this